Logo

KRMD

KORU Medical Systems, Inc.

KRMD

KORU Medical Systems, Inc. • NASDAQ
$5.92 ▲ 2.07% (+0.12)
Market Cap $273.81 M
52w High $5.95
52w Low $1.86
Dividend Yield 0%
P/E -74
Volume 195.23K
Outstanding Shares 46.25M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $10.402M ▲ $6.928M ▲ $-777.966K ▼ -7.479% ▼ $-0.017 ▼ $-573.634K ▼
Q2-2025 $10.195M ▲ $6.788M ▼ $-206.867K ▲ -2.029% ▲ $-0.004 ▲ $-103.168K ▲
Q1-2025 $9.635M ▲ $7.291M ▲ $-1.166M ▲ -12.104% ▲ $-0.03 ▲ $-1.028M ▲
Q4-2024 $8.839M ▲ $7.152M ▲ $-1.561M ▲ -17.663% ▲ $-0.034 ▲ $-1.494M ▼
Q3-2024 $8.18M $6.889M $-1.581M -19.325% $-0.035 $-1.476M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.464M ▲ $27.104M ▲ $10.639M ▲ $16.465M ▼
Q2-2025 $8.055M ▼ $25.516M ▼ $8.99M ▼ $16.526M ▲
Q1-2025 $8.736M ▼ $27.216M ▼ $10.871M ▲ $16.345M ▼
Q4-2024 $9.581M ▲ $27.219M ▼ $10.405M ▲ $16.814M ▼
Q3-2024 $8.806M $27.39M $9.657M $17.733M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-777.966K ▼ $65.456K ▲ $-52.483K ▼ $396.33K ▲ $409.303K ▲ $12.97K ▲
Q2-2025 $-206.867K ▲ $-460.34K ▼ $-28.814K ▲ $-191.964K ▼ $-681.118K ▲ $-489.154K ▲
Q1-2025 $-1.166M ▲ $-237.467K ▼ $-446.838K ▼ $-160.808K ▲ $-845.113K ▼ $-680.905K ▼
Q4-2024 $-1.561M ▲ $939.615K ▲ $50.738K ▲ $-215.716K ▼ $774.637K ▲ $983.182K ▲
Q3-2024 $-1.581M $-923.948K $-1.102M $374.454K $-1.652M $-2.008M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been fairly steady over the past several years, showing only modest growth rather than a strong upward trajectory. Gross profit has held up reasonably well, suggesting the core product line carries decent margins. The main financial challenge is that operating expenses, likely driven by R&D, commercialization, and overhead, have kept the company in a small but consistent loss position. Net losses and per‑share losses have fluctuated but remain present, with some recent improvement, which hints at better cost control or slightly higher scale, but not yet a clear, sustained move into profitability.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and conservative. The company carries no debt, which reduces financial risk and gives it flexibility during slower periods. It maintains a modest asset base with a cash position that has come down from earlier years but still appears adequate for a small business at its current scale. Shareholders’ equity has gradually declined as losses accumulate, reflecting ongoing investment and spending ahead of revenue growth. Overall, the company looks lean and underleveraged, but it does not have a large buffer if losses were to widen for several years.

Cash Flow

Cash Flow Cash flow has hovered around break‑even, with small swings between slight inflows and modest outflows. Operating cash flow has generally tracked the income statement, showing that reported losses are largely mirrored in cash terms rather than being purely accounting noise. Capital spending needs appear low, so free cash flow is mostly a function of how well the company manages its operating costs versus revenue. This profile suggests a business that is not burning cash aggressively but also not yet generating durable, surplus cash to reinvest or return to shareholders.

Competitive Edge

Competitive Edge KORU sits in a focused niche within medical devices: large‑volume subcutaneous infusion, especially for chronic therapies that can move from clinics into the home. Its FREEDOM system has been in the market for many years and has built up an entrenched installed base with high patient adherence, which makes switching to alternatives less attractive. The razor/razor‑blade model (durable pumps plus recurring disposables) supports recurring revenue and customer stickiness. Regulatory clearances for use with specific drugs, plus partnerships with pharmaceutical companies, create barriers for new entrants. The flip side is that KORU is still a small player in a world dominated by much larger medtech firms, and it is heavily exposed to a limited set of therapies and reimbursement frameworks, which concentrates its risk.

Innovation and R&D

Innovation and R&D Innovation is clearly a core part of the strategy. The FREEDOM platform is deliberately simple, mechanical, and patient‑friendly, which differentiates it from more complex infusion technologies. KORU has leaned into working with drug makers, not just selling hardware, by supporting clinical trials and tailoring its system to new biologic therapies and formats like prefilled syringes. The next‑generation system being co‑developed with Schott Pharma aims to keep the platform aligned with where biologic drug delivery is heading. Efforts to move beyond immunoglobulin into areas such as nephrology and oncology, as well as to grow internationally, indicate a willingness to expand the addressable market. The main uncertainty is execution: turning collaborations and trials into commercialized, on‑label uses takes time, regulatory success, and sustained R&D investment, which can weigh on near‑term profits.

Summary

KORU Medical combines a focused, patient‑friendly technology platform with a recurring revenue model and a conservative, debt‑free balance sheet. Financially, the company is still in the “build” phase: revenue is steady but not yet scaling rapidly, and ongoing investment in growth and innovation keeps it in a modest loss and near break‑even cash flow position. Strategically, it benefits from a sticky installed base, regulatory clearances with specific drugs, and deep ties to pharmaceutical partners, all of which support a durable niche in home‑based infusion. Future value creation will largely depend on its ability to broaden its therapy footprint, successfully commercialize its pharma collaborations, expand outside its core markets, and eventually convert its innovation pipeline into sustained, profitable growth while maintaining financial discipline.

NEWS

November 17, 2025 · 4:05 PM UTC

KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025

Read more

November 13, 2025 · 8:00 AM UTC

KORU Medical Systems to Participate in Upcoming Investor Conferences

Read more

November 12, 2025 · 4:05 PM UTC

KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance

Read more

November 4, 2025 · 4:05 PM UTC

KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems

Read more

October 22, 2025 · 4:05 PM UTC

KORU Medical Systems to Report Third Quarter 2025 Financial Results on November 12, 2025

Read more